Browse by category

More than a quarter of people with Type 2 diabetes take glucagon-like peptide-1 (GLP-1), but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a study by Stanford Medicine scientists and their collaborators. The genetic variants, carried by roughly 10% of the general population, cause a surprising and still mysterious phenomenon that researchers refer to as GLP-1 resistance, in which levels of the hormone GLP-1, which